VG Life Sciences Announces Positive Safety Results in Solid Tumor Clinical Test

VG Life Sciences Inc (OTCPINK:VGLS) announced that stage 2 of the Pre-IND Phase 1 Study showed positive results in relation to tolerability and toxicity in patients with advanced stage solid tumors.

As quoted in the press release:

Haig Keledjian, CEO of VG Life Sciences, said, “We are happy to report we attained the safety endpoints we anticipated for our second cohort of patients.  Similar to the positive results we announced previously for our first patient cohort, no significant toxicities were observed at a higher dose of HCQ in combination with sorafenib.  We have begun enrolling patients into the next dosing cohort in this dose-escalation study and look forward to reporting those results in a timely fashion.  We anticipate patient recruitment to accelerate since opening up the enrollment criteria to include patients with breast, colon, lung, liver, pancreatic, and ovarian cancer, and look forward to an ultimate study completion date, from a safety standpoint, of third quarter 2013.

Click here to read the full VG Life Sciences Inc (OTCPINK:VGLS) press release.